• Nov. 29, 2016, 10:31 AM
    • Albany Molecular Research (AMRI +1%) inks a multi-year supply agreement for an undisclosed product in its portfolio with Shire plc's (SHPG +1.1%) U.S. Manufacturing unit. Terms are confidential.
    • AMRI has been supplying a neuroscience product to Shire under a separate agreement. The companies have a long-term partnership in product development and manufacturing.
    Nov. 29, 2016, 10:31 AM
  • Nov. 8, 2016, 7:31 AM
    • Albany Molecular (NASDAQ:AMRI): Q3 EPS of $0.17 beats by $0.04.
    • Revenue of $152.74M (+46.1% Y/Y) misses by $8.01M.
    • Press Release
    Nov. 8, 2016, 7:31 AM
  • Aug. 4, 2016, 7:45 AM
    • Albany Molecular (NASDAQ:AMRI): Q2 EPS of $0.36 beats by $0.04.
    • Revenue of $120.81M (+34.9% Y/Y) misses by $2.29M.
    • Press Release
    Aug. 4, 2016, 7:45 AM
  • May 10, 2016, 7:37 AM
    • Albany Molecular (NASDAQ:AMRI): Q1 EPS of $0.07 misses by $0.14.
    • Revenue of $105.58M (+29.0% Y/Y) misses by $1.62M.
    May 10, 2016, 7:37 AM
  • Feb. 17, 2016, 7:32 AM
    • Albany Molecular (NASDAQ:AMRI): Q4 EPS of $0.40 beats by $0.04.
    • Revenue of $126.41M (+46.0% Y/Y) misses by $6.99M.
    Feb. 17, 2016, 7:32 AM
  • Dec. 15, 2015, 10:08 AM
    • (AMRI +3.1%) buys testing services provider Whitehouse Laboratories for $54M in cash plus an additional $2M in AMRI stock contingent on the achievement of certain 2015 targets.
    • Lebanon, NJ-based Whitehouse's menu of services includes chemical and material analysis, method development and validation and quality control verification to the pharmaceutical, medical device and personal care industries.
    • The deal should be accretive to AMRI's 2016 non-GAAP EPS. Updated guidance will be provided in mid-February.
    Dec. 15, 2015, 10:08 AM
  • Nov. 5, 2015, 7:13 AM
    • Albany Molecular (NASDAQ:AMRI): Q3 EPS of $0.14 beats by $0.01.
    • Revenue of $104.6M (+67.4% Y/Y) beats by $9.45M.
    Nov. 5, 2015, 7:13 AM
  • Aug. 4, 2015, 7:40 AM
    • Albany Molecular (NASDAQ:AMRI): Q2 EPS of $0.22 beats by $0.04.
    • Revenue of $89.55M (+31.3% Y/Y) beats by $4.55M.
    Aug. 4, 2015, 7:40 AM
  • May 5, 2015, 7:43 AM
    • Albany Molecular (NASDAQ:AMRI): Q1 EPS of $0.20 beats by $0.05.
    • Revenue of $81.82M (+37.9% Y/Y) beats by $0.32M.
    May 5, 2015, 7:43 AM
  • Feb. 12, 2015, 7:54 AM
    • Albany Molecular (NASDAQ:AMRI): Q4 EPS of $0.28 misses by $0.05.
    • Revenue of $86.6M (+29.0% Y/Y) misses by $5.3M.
    Feb. 12, 2015, 7:54 AM
  • Jan. 15, 2015, 4:53 PM
    • (NASDAQ:AMRI) VP and CFO Michael M. Nolan resigns effective at the end of February. The company appoints Felicia Ladin as CFO effective February 4. Previously, she was SVP and CFO, Global Specialty Medicines at Teva Pharmaceuticals, USA.
    Jan. 15, 2015, 4:53 PM
  • Jan. 15, 2015, 7:41 AM
    • (NASDAQ:AMRI) acquires Aptuit's Glasgow, U.K.-based drug formulation and clinical stage manufacturing business and its West Lafayette, IN-based drug formulation operation for $60M.
    • Under the terms of the deal, AMRI will pay $24M for the Glasgow business and $36M for the Indiana business plus assume certain liabilities. The acquisitions should contribute $25M - 30M to revenue and $5M - 7M to non-GAAP EBITDA this year. The transaction is expected to close this quarter.
    • AMRI will provide updated guidance when it releases Q4 and 2014 results in February.
    Jan. 15, 2015, 7:41 AM
  • Nov. 5, 2014, 12:49 PM
    Nov. 5, 2014, 12:49 PM
  • Nov. 5, 2014, 7:43 AM
    • Albany Molecular (NASDAQ:AMRI): Q3 EPS of -$0.02 misses by $0.18.
    • Revenue of $62.47M (+2.8% Y/Y) misses by $8.53M.
    Nov. 5, 2014, 7:43 AM
  • Aug. 5, 2014, 6:55 PM
    • Albany Molecular (NASDAQ:AMRI): Q2 EPS of $0.22 beats by $0.02.
    • Revenue of $68.2M (+15.0% Y/Y) beats by $2.6M.
    Aug. 5, 2014, 6:55 PM
  • Jun. 2, 2014, 1:14 PM
    • AMRI (AMRI +3.9%) acquires Oso Biopharmaceuticals Manufacturing LLC (OsoBio) for $110M cash. OsoBio is a contract manufacturer of injectable drug products, including sterile liquid, suspension and lyophilized formulations. President & CEO William S. Marth says, "The acquisition of OsoBio is highly complementary to our finished dose manufacturing business and is consistent with our strategy to be the preeminent supplier of custom and complex drug development services and products to the pharmaceutical industry."
    • On a stand-alone basis, OsoBio's 2014 revenue is expected to be $58M - 60M and EBITDA between $9M - 10M.
    Jun. 2, 2014, 1:14 PM